A boost for Sirtex Medical (ASX:SRX) after announcing that unaudited worldwide dose sales of SIR-Spheres Y-90 resin microspheres for the 12 months ended 30 June 2016 increased 16.4 per cent over the prior corresponding period (pcp).
Investors responded by boosting the company's share price by 10 per cent.
The company said the growth delivered was at the upper end of the 15-17 per cent dose sales guidance provided on 1 June.
"The Americas recorded second half and full year dose sales growth of 19.2% and 19.0%, respectively; also within previous guidance," said the company. "EMEA recorded full year dose sales growth of 11.2% and APAC showed growth of 8.9% over the pcp."
Mr Gilman Wong, Chief Executive Officer of Sirtex Medical, said: “The strong double digit growth in global dose sales reflects the continued momentum we have acheived in this large, underpenetrated market opportunity for SIR-Spheres microspheres.”
Sirtex will report its 2016 financial year results on 24 August 2016.